On April 25, 2023 bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer, reported that it will present at the Cleveland Clinic’s invitation-only Advances in Early Lung Cancer Detection annual symposium in Cleveland, Ohio, on April 27, 2023 (Press release, BioAffinity Technologies, APR 25, 2023, View Source [SID1234630464]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation by Vivienne I. Rebel, MD, PhD, bioAffinity Technologies Executive Vice President and Chief Science and Medical Officer, will focus on advancements in CyPath Lung, the Company’s noninvasive test for detection of early-stage lung cancer. CyPath Lung uses flow cytometry and artificial intelligence to analyze the lung microenvironment to identify cell populations that accurately predict cancer in patients at high risk for lung cancer.

The fourth annual Advances in Early Lung Cancer Detection symposium brings together global leaders in the field of lung cancer, including physicians, advocates and industry, to accelerate the development and implementation of new technologies and methods to find lung cancer at the earliest stages when it is most treatable. This is bioAffinity Technologies’ fourth invitation to present before symposium attendees.